Indaptus Therapeutics, Inc. (INDP)

Market Cap	405.41M +7,845.8%
Revenue (ttm)	n/a
Net Income	-18.86M
EPS	-5.27
Shares Out	113.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	575,176
Open	3.520
Previous Close	3.570
Day's Range	3.200 - 3.850
52-Week Range	0.920 - 19.914
Beta	1.27
Analysts	Buy
Price Target	10.00 (+179.33%)
Earnings Date	May 15, 2026

About INDP

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: INDP
• Website: https://indaptusrx.com

Analyst Summary

According to one analyst, the rating for INDP stock is "Buy" and the 12-month stock price target is $10.0.

Price Target

$10.0

(179.33% upside)

Analyst Consensus: Buy